淡江大學機構典藏:Item 987654321/78544
English  |  正體中文  |  简体中文  |  全文笔数/总笔数 : 62830/95882 (66%)
造访人次 : 4048210      在线人数 : 590
RC Version 7.0 © Powered By DSPACE, MIT. Enhanced by NTU Library & TKU Library IR team.
搜寻范围 查询小技巧：
  • 您可在西文检索词汇前后加上"双引号"，以获取较精准的检索结果
  • 若欲以作者姓名搜寻，建议至进阶搜寻限定作者字段，可获得较完整数据
    •  进阶搜寻


    jsp.display-item.identifier=請使用永久網址來引用或連結此文件: https://tkuir.lib.tku.edu.tw/dspace/handle/987654321/78544


    题名: Clozapine Protects Bone Mineral Density in Female Patients with Schizophrenia
    作者: Lin, Chieh-hsin;Huang, Kuo-hao;Chang, Yue-cune;Huang, Yi-chen;Hsu, Wan-chih;Lin, Chun-yuan;Chou, Frank Huang-chih;Tsai, Guochuan E.;Lane, Hsien-yuan
    贡献者: 淡江大學數學學系
    关键词: Bone mineral density;clozapine;osteoporosis;prolactin;schizophrenia
    日期: 2012-08-01
    上传时间: 2012-10-11 19:34:38 (UTC+8)
    出版者: Cambridge: Cambridge University Press
    摘要: Decreased bone mineral density (BMD) is common in patients with schizophrenia; however, the pathogenesis is unclear. Different classes of antipsychotic agents may affect BMD. This study systemically examined the effects of clozapine vs. other antipsychotics, and several hormonal and metabolic factors that may contribute to BMD in female patients with schizophrenia, who are more vulnerable than males. Forty-eight women with schizophrenia, treated with long-term antipsychotics of the prototype prolactin-sparing (PS) antipsychotic agent clozapine vs. prolactin-raising (PR) antipsychotics were enrolled. They were matched for demographic and clinical characteristics. Various factors, including blood levels of prolactin and sex hormones, psychopathological symptoms, global assessment of functioning, physical activity, and menopausal status, were determined to explore their contribution to low BMD (LBMD), defined as a dual-energy X-ray absorptiometer (DEXA) T score ＜ -1. Overall, women receiving clozapine have better bone density than women receiving PR antipsychotics. Compared to PR antipsychotics, PS clozapine therapy is a protective factor (odds ratio 28.2, 95% confidence interval 2.37-336.10, p=0.008) for LBMD. Predictors for higher bone density in the clozapine group included higher clozapine dose (p＜0.001), younger age (p＜0.001), and higher thyroid-stimulating hormone level (p＜0.001); in the PR group, higher body mass index (p=0.003) and lower alkaline phosphatase level (p=0.007) were associated with LBMD. This study suggests that clozapine treatment is beneficial for BMD compared to PR antipsychotic treatment in women with chronic schizophrenia, and clozapine's bone-density protecting effect is dose-related.
    關聯: The International Journal of Neuropsychopharmacology 15(7), pp.897-906
    DOI: 10.1017/S1461145711001507
    显示于类别:[數學學系暨研究所] 期刊論文

    文件中的档案:

    档案 描述 大小格式浏览次数
    109. International Journal of Neuropsychopharmacology(clo BMD IJNP online2011).pdf3937KbAdobe PDF445检视/开启
    index.html0KbHTML145检视/开启

    在機構典藏中所有的数据项都受到原著作权保护.

    TAIR相关文章

    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library & TKU Library IR teams. Copyright ©   - 回馈